




(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/05/25 (87) Date publication PCT/PCT Publication Date: 2018/11/29 (85) Entrée phase nationale/National Entry: 2019/11/26 (86) N° demande PCT/PCT Application No.: CA 2018/050614 (87) N° publication PCT/PCT Publication No.: 2018/213934 (30) Priorité/Priority: 2017/05/26 (US62/511,729)	(51) Cl.Int./Int.Cl. <i>C07K 19/00</i> (2006.01), <i>A61K 38/17</i> (2006.01), <i>A61K 39/00</i> (2006.01), <i>A61K 9/10</i> (2006.01), <i>A61L 27/52</i> (2006.01), <i>A61L 27/54</i> (2006.01), <i>A61P 17/02</i> (2006.01), <i>A61P 31/04</i> (2006.01), <i>A61P 37/02</i> (2006.01), <i>C07K 14/00</i> (2006.01), <i>C07K 14/47</i> (2006.01), <i>C07K 7/08</i> (2006.01), <i>C12N 5/078</i> (2010.01) (71) Demandeurs/Applicants: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA, CA; NATIONAL RESEARCH COUNCIL OF CANADA, CA (72) Inventeurs/Inventors: UNSWORTH, LARRY D., CA; ...
---	--

(54) Titre : PEPTIDE AUTO-ASSEMBLE SERVANT A ACTIVER DES MASTOCYTES HUMAINS
(54) Title: SELF-ASSEMBLING PEPTIDE FOR ACTIVATING HUMAN MAST CELLS


(RADA)₄: AC-RADARADARADARADA-CONH₂:



(SEQ ID NO: 1) **FIG. 1A**

(RADA)₄-GG-(PAMP-12): AC-RADARADARADARADA-GG-FRKKWNKWALSR-CONH₂

(SEQ ID NO: 2) **FIG. 1B**



(SEQ ID NO: 2) **FIG. 1C**

(57) **Abrégé/Abstract:**
The present disclosure relates to bioactive self-assembling peptides, nanofibers and hydrogels for activating human mast cells. The peptides, nanofibers and hydrogels comprise a self-assembling peptide that mediates self-assembly linked to a MrgX2 agonist peptide; for example, (RADA)₄ linked to proadrenomedullin-12 (PAMP-12).

(72) Inventeurs(suite)/Inventors(continued): LU, LEI, CA; KULKA, MARIANNA, CA

(74) Agent: BORDEN LADNER GERVAIS LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(10) International Publication Number
WO 2018/213934 A1(43) International Publication Date
29 November 2018 (29.11.2018)

(51) International Patent Classification:

C07K 19/00 (2006.01) **A61P 31/04** (2006.01)
A61K 38/17 (2006.01) **A61P 37/02** (2006.01)
A61K 39/00 (2006.01) **C07K 14/00** (2006.01)
A61K 9/10 (2006.01) **C07K 14/47** (2006.01)
A61L 27/52 (2006.01) **C07K 7/08** (2006.01)
A61L 27/54 (2006.01) **C12N 5/078** (2010.01)
A61P 17/02 (2006.01)

(21) International Application Number:

PCT/CA2018/050614

(22) International Filing Date:

25 May 2018 (25.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/511,729 26 May 2017 (26.05.2017) US

(71) Applicants: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA [CA/CA]; 4000 TEC Centre, 10230 Jasper Avenue, Edmonton, Alberta T5J 4P6 (CA). NATIONAL RESEARCH COUNCIL OF CANADA [CA/CA]; 1200 Montreal Road, Ottawa, Ontario K1A 0R6 (CA).


(72) Inventors: UNSWORTH, Larry, D.; 17 Aspen Crescent, St. Albert, Alberta T6G 1H4 (CA). LU, Lei; #104, 9930 Bellamy Hill Road NW, Edmonton, Alberta T5K 2B5 (CA). KULKA, Marianna; 3601 65th Street, Beaumont, Alberta T4X 0G6 (CA).

(74) Agent: VICKERS, Mark F. et al.; Borden Ladner Gervais LLP, 100 Queen Street, Suite 1300, Ottawa, Ontario K1P 1J9 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: SELF-ASSEMBLING PEPTIDE FOR ACTIVATING HUMAN MAST CELLS

(RADA)₄: AC-RADARADARADARADA-CONH₂:


(SEQ ID NO: 1)

FIG. 1A

(RADA)₄-GG-(PAMP-12): AC-RADARADARADARADA-GG-FRKKWKNWALSR-CONH₂:

(SEQ ID NO: 2)

FIG. 1B



(SEQ ID NO: 2)

FIG. 1C

(57) Abstract: The present disclosure relates to bioactive self-assembling peptides, nanofibers and hydrogels for activating human mast cells. The peptides, nanofibers and hydrogels comprise a self-assembling peptide that mediates self-assembly linked to a MrgX2 agonist peptide; for example, (RADA)₄ linked to proadrenomedullin-12 (PAMP-12).

[Continued on next page]

WO 2018/213934 A1



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

SELF-ASSEMBLING PEPTIDE FOR ACTIVATING HUMAN MAST CELLS**CROSS REFERENCE TO RELATED APPLICATION**

5 [0001] This application claims priority to US 62/511,729, filed May 26, 2017, the entire contents of which is hereby incorporated by reference.

FIELD

10 [0002] The present disclosure relates generally to self-assembling peptides for activating human mast cells.

BACKGROUND

[0003] Traditionally, mast cells are best known for their important role in allergic inflammatory responses, however, mast cells also participate in protective actions such as wound healing, angiogenesis and host defense against pathogens and animal venoms 15 [1-5]. Mature mast cells are distributed widely in connective tissues that interface with the external environment throughout the body: skin, digestive tract, mucosa of lung and airways, etc. [6, 7]. These cells contain a number of secretory granules, which are filled with a large amount of pre-formed and pre-activated compounds like histamine, heparin and serine proteases, cytokines and growth factors [1, 8]. Upon stimulation, mast cell 20 degranulation occurs and leads to the rapid release of pre-stored and neo-synthesized mediators. Therefore, mast cells can be considered as the first responders that play a critical role in both host defense and tissue repair.

SUMMARY

25 [0004] In one aspect there is described a bioactive self-assembling peptide, comprising: a first peptide comprising a self-assembling peptide that mediates self-assembly; and a second peptide comprising a MrgX2 agonist.

[0005] In one example, the bioactive self-assembling peptide of claim 1, further comprising a linker positioned between said first peptide and said second peptide.

30 [0006] In one aspect there is described a bioactive self-assembling peptide, comprising: a first peptide comprising a self-assembling peptide that mediates self-assembly; and a second peptide comprising a MrgX2 agonist; and a linker positioned between said first peptide and said second peptide.

[0007] In one example, the bioactive self-assembling peptide of any preceding 35 claim, wherein said linker comprises a peptide, preferably at least two peptides.

- [0008] In one example, the bioactive self-assembling peptide of any preceding claim, wherein said linker comprises the amino acid sequence Gly-Gly.
- [0009] In one example, the bioactive self-assembling peptide of any preceding claim, wherein said first peptide comprises the peptide (RADA)₄ (SEQ ID NO: 1).
- 5 [0010] In one example, the bioactive self-assembling peptide of any preceding claim, wherein said second peptide comprises PAMP₁₂.
- [0011] In one aspect there is described a nanofiber comprising a bioactive self-assembling peptide according to any preceding claim.
- [0012] In one aspect there is described a hydrogel comprising a bioactive self-assembling peptide according to any one of claims 1 to 8, and a liquid.
- 10 [0013] In one example, the hydrogel of claim 9, comprising at least about 20% (w/w) said bioactive self-assembling peptide.
- [0014] In one aspect there is described a hydrogel comprising a bioactive self-assembling peptide according to any one of claims 1 to 8, a self-assembling peptide, and
- 15 a liquid.
- [0015] In one example, the hydrogel of claim 11, comprising at least about 20%(w/w) said bioactive self-assembling peptide.
- [0016] In one aspect there is described a use of a bioactive self-assembling peptide according to any one of claims 1-8, for activation of a mast cell in a subject.
- 20 [0017] In one aspect there is described a use of a bioactive self-assembling peptide according to any one of claims 1-8, for the treatment of a bacterial infection in a subject.
- [0018] In one aspect there is described a use of a bioactive self-assembling peptide according to any one of claims 1-8, for the treatment of a wound in a subject.
- 25 [0019] In one aspect there is described a use of a nanofiber of claim 9, for activation of a mast cell in a subject.
- [0020] In one aspect there is described a use of a nanofiber of claim 9, for the treatment of a bacterial infection in a subject.
- [0021] In one aspect there is described a use of a nanofiber of claim 9, for the
- 30 treatment of a wound a subject.
- [0022] In one aspect there is described a use of a hydrogel of any one of claims 10 to 13, for activation of a mast cell in a subject.
- [0023] In one aspect there is described a use of a hydrogel of any one of claims 10 to 13, for the treatment of a bacterial infection in a subject.

- [0024] In one aspect there is described a use of a hydrogel of any one of claims 10 to 13, for the treatment of a wound in a subject.
- [0025] In one aspect there is described a use of a bioactive self-assembling peptide according to any one of claims 1-8, in the manufacture of a medicament for
5 activation of a mast cell in a subject.
- [0026] In one aspect there is described a use of a bioactive self-assembling peptide according to any one of claims 1-8, in the manufacture of a medicament for the treatment of a bacterial infection in a subject.
- [0027] In one aspect there is described a use of a bioactive self-assembling
10 peptide according to any one of claims 1-8, in the manufacture of a medicament for the treatment of a wound in a subject.
- [0028] In one example, the use of any one of claims 14 to 25, further comprising use of an antibiotic.
- [0029] In one aspect there is described a use of a nanofiber of claim 9, in the
15 manufacture of a medicament for activation of a mast cell in a subject.
- [0030] In one aspect there is described a use of a nanofiber of claim 9, in the manufacture of a medicament for the treatment of a bacterial infection in a subject.
- [0031] In one aspect there is described a use of a nanofiber of claim 9, in the manufacture of a medicament for the treatment of a wound in a subject.
- 20 [0032] In one aspect there is described a use of a hydrogel of any one of claims 10 to 13, in the manufacture of a medicament for activation of a mast cell in a subject.
- [0033] In one aspect there is described a use of a hydrogel of any one of claims 10 to 13, in the manufacture of a medicament for the treatment of a bacterial infection in a subject.
- 25 [0034] In one aspect there is described a use of a hydrogel of any one of claims 10 to 13, in the manufacture of a medicament for the treatment of a wound a subject.
- [0035] In one example, the use of any one of claims 27-32, further comprising use of an antibiotic in the manufacture of a medicament for the treatment of a bacterial infection.
- 30 [0036] In one example, the use of anyone of claims 14 to 33, wherein said subject is a human.
- [0037] In one aspect there is described a method of treating a bacterial infection, comprising: administering a bioactive self-assembling peptide according to any one of claims 1-8 to a subject in the need thereof.

- [0038] In one aspect there is described a method of treating a bacterial infection, comprising: administering a nanofiber of claim 9 to a subject in the need thereof.
- [0039] In one aspect there is described a method of treating a bacterial infection, comprising: administering a hydrogel of any one of claims 10 to 13, to a subject in the
5 need thereof.
- [0040] In one example, the method of any one of claims 35 to 37, further comprising administering an antibiotic.
- [0041] In one example, the method of any one of claims 35 to 38, wherein said subject is a human.
- 10 [0042] In one aspect there is described a method of treating a wound in a subject, comprising: administering a bioactive self-assembling peptide according to any one of claims 1-8 to a subject in the need thereof.
- [0043] In one aspect there is described a method of treating a wound in a subject, comprising: administering a nanofiber of claim 9 to a subject in the need thereof.
- 15 [0044] In one aspect there is described a method of treating a wound in a subject, comprising: administering a hydrogel of any one of claims 10 to 13, to a subject in the need thereof.
- [0045] In one example, the method of any one of claims 40 to 42, further comprising administering an antibiotic.
- 20 [0046] In one example, the method of any one of claims 40 to 43, wherein said subject is a human.
- [0047] In one aspect there is described a kit comprising: a bioactive self-assembling peptide according to any one of claims 1 to 8, a container, and optionally instructions for the use thereof.
- 25 [0048] In one aspect there is described a kit comprising: a nanofiber of claim 9, a container, and optionally instructions for the use thereof.
- [0049] In one aspect there is described a kit comprising: a hydrogel according to any one of claims 10 to 13, a container, and optionally instructions for the use thereof.
- [0050] In one example, the kit of any one of claims 45 to 47, further comprising an
30 antibiotic.

BRIEF DESCRIPTION OF THE FIGURES

[0051] Embodiments of the present disclosure will now be described, by way of example only, with reference to the attached Figs.

- [0052]** Fig. 1 depicts the chemical structure of self-assembling peptides, (A) (RADA)₄ (SEQ ID NO: 1), (B&C) (RADA)₄GG(PAMP12) (SEQ ID NO:2) .
- [0053]** Fig. 2 depicts the schematic of the hydrogel matrix with both (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) self-assembling peptides.
- 5 **[0054]** Fig. 3 the morphology of 0.5% w/v self-assembling peptide matrix measured by AFM. The ratio of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) : (RADA)₄ (SEQ ID NO: 1) was: a) 0:100; b) 10:90; c) 20:80; d) 40:60; e) 80:20; f) 100: 0, g) the height of (RADA)₄ nanofiber, h) the height of (RADA)₄-GG-(PAMP-12) nanofiber. The sections were followed with the white arrow shown in a) and f). The examples of thicker sections of the nanofiber in b), c) and d) were highlighted by red arrows.
- 10 **[0055]** Fig. 4 The optimal response of LAD2 cells to PAMP-12, (RADA)₄(SEQ ID NO: 1), and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) on mast cell degranulation. LAD2 cells were activated with peptides for 30 min and β -hex release was measured. Data represent mean $\pm$ 1 SEM, for $n \geq 3$ repeats.
- 15 **[0056]** Fig. 5 The effect of self-assembling hydrogel matrices with different ration of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) on LAD2 degranulation. Data represent mean $\pm$ 1 SEM, for $n \geq 3$ repeats.
- [0057]** Fig. 6 Hydrogel matrix with 20% w/w of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) induce mast cell degranulation locally. A). Schematic diagram of co-culture by well insert with 0.2 μ m pore size filter. B). The effect of co-cultured PAMP-12 or hydrogel matrices on LAD2 degranulation. Data represent mean $\pm$ 1 SEM, for $n \geq 3$ repeats.
- 20 **[0058]** Fig. 7 Laser confocal scanning microscopy image of LAD2 cells and 0.5% w/v nanfiber matrices. F-actin (green – some examples shown with leader line with single arrow) and nuclei (blue – some examples shown with leader line with double arrows). (a, c) with pure (RADA)₄ (SEQ ID NO: 1); (b, d) with 20% w/w of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2). (a, b) 3D distribution of cells in contact with hydrogel matrices. The Z-dimension scale was determined by the first and the last visible cell nuclei; (c, d) 2D images of cell morphology and F-actin organization.
- 25 **[0059]** Fig. 8 Effect of hydrogel matrix on mast cell viability as determined using XTT assay, where cell viability of control at 4 h is 100%. Data represent mean $\pm$ 1 SEM, for $n \geq 3$ repeats.
- 30 **[0060]** Fig. 9 a) Immunofluorescent staining of human skin. Nuclei (blue - some examples shown with leader line with double arrows), mast cell tryptase (red - some examples shown with leader line with single arrow). b) ddPCR analysis of TPSAB1 (tryptase) mRNA for human skin tissue treated with hydrogel matrices or PAMP-12 for 4
- 35

h. Expression was normalized with the expression of ACTB. NS: normal skin, NSE: normal skin without epidermis, NSE/PAMP-12: NSE with 10 μ M PAMP-12, NSE/(RADA)4: NSE with pure (RADA)4 hydrogel matrix, NSE/(RADA)₄-GG-(PAMP-12): NSE with hydrogel matrix contain 20% w/w (RADA)₄-GG-(PAMP-12). Data represent mean $\pm$ 1 SEM, for n $\geq$ 3 repeats.

DETAILED DESCRIPTION

- [0061]** Generally, the present disclosure provides compounds, compositions, methods, and uses, for mast cell activation in a subject.
- 10 **[0062]** In one example, the compounds, compositions, methods, and uses, for mast cell activation are used in the treatment of a bacterial infection in a subject.
- [0063]** There term "subject" as used herein refers to an animal. In some examples, the animal is a mammal. Non-limiting examples of mammals include a human; a non-human primate; a companion animal such as a mouse, rat, dog, cat, hamster, guinea pig, rabbit; livestock such a cow, sheep, horse, pig, chicken; and the like. A subject may also be referred to as a patient.
- 15 **[0064]** In some examples, there is described a bioactive self-assembling peptide, comprising: a first peptide comprising a self-assembling peptide that mediates self-assembly; and a second peptide comprising a MrgX2 agonist.
- 20 **[0065]** In one example, the bioactive self-assembling peptide further comprises a linker positioned between said first peptide and said second peptide.
- [0066]** In some examples, there is described a bioactive self-assembling peptide, comprising: a first peptide comprising a self-assembling peptide that mediates self-assembly; and a second peptide comprising a MrgX2 agonist; and a linker positioned between said first peptide and said second peptide.
- 25 **[0067]** In some examples bioactive the self-assembling peptide is for use in mast cell activation in a subject.
- [0068]** In one example, the bioactive self-assembling peptide is for use in the treatment of a bacterial infection in a subject.
- 30 **[0069]** In one example, the bioactive self-assembling peptide forms nanofibers.
- [0070]** In one example, the nanofiber(s) produced from the bioactive self-assembling peptides is for use in mast cell activation in a subject.
- [0071]** In one example, the nanofiber(s) produced from the bioactive self-assembling peptides are for use in the treatment of a bacterial infection in a subject.

[0072] In one example, the bioactive self-assembling peptide(s) as described herein is used to prepare a hydrogel for mast cell activation.

[0073] In one example, the bioactive self-assembling peptide(s) as described herein is used to prepare a hydrogel for mast cell activation, for use in the treatment of a bacterial infection in a subject.

[0074] In one example, the bioactive self-assembling peptide is for the preparation of a medicament for use in the treatment of a bacterial infection in a subject.

[0075] The terms "peptide", "polypeptide," and "protein" are used interchangeably to refer to a polymer of amino acid residues. The terms also apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The terms encompass any peptide (including cyclic peptides) or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins.

[0076] A peptide may contain amino acids other than the 20 gene-encoded amino acids. When amino acids are not designated as either D- or L-amino acids, the amino acid is either an L-amino acid or could be either a D- or L-amino acid, unless the context requires a particular isomer.

[0077] Peptides can be produced using methods known in the art, e.g., by purifying the peptide sequence from a naturally occurring protein or peptide. Purification can be performed along with a cleavage or degradation (either enzymatic or non-enzymatic) to produce the desired peptide using methods known in the art.

[0078] Alternatively, products can be biochemically synthesized using, e.g., solid phase synthesis, partial solid phase synthesis methods, fragment condensation, classical solution synthesis.

[0079] Peptides may also be prepared, for example, by isolation from genetically engineered host cells comprising expression systems. For example, peptides described herein may be produced by expressing in a cell (e.g., a yeast, bacterial, mammalian, or insect cell) a vector containing a polynucleotide that encodes a peptide under condition in which the peptide is expressed. Means for preparing such peptides are well understood in the art.

[0080] Peptides of the present disclosure also include variants of the aforementioned peptides, including all allelic forms and splice variants. Such peptides

vary from the reference peptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof.

[0081] The term "self-assembling" refers to the capability of one or more molecules in a compound to spontaneously assemble, or organize, to form a high ordered structure. For example, a plurality of molecules of a compound in which a disordered system forms a more organized structure or pattern as a consequence of specific, local interactions among the molecules themselves, without external direction. In a specific example, a "self-assembling peptide" refers to the capacity of amino acid residues in a peptide to spontaneously assemble, or organize, to form a higher order structure. In one example, the higher order structure is a nanofiber. In one example, the higher order structure is a hydrogel.

[0082] In a specific example, the first peptide comprises a (RADA)₄ peptide (RADARADARADARADA) (SEQ ID NO: 1).

[0083] In the case of (RADA)₄ (SEQ ID NO: 1), while not wishing to be bound by theory, it is thought alternating hydrophobic and hydrophilic amino acids form well-ordered β -sheet nanofibers through self-assembly.

[0084] The term "linker" as used herein refers to an agent or molecule that connects said first peptide and said second peptide. In one example, the linker covalently connects said first peptide to said second peptide. In another example, the linked non-covalently connects said first peptide to said second peptide.

[0085] In one example, the linker refers to an amino acid sequence that connects or links the first peptide and second peptide.

[0086] In one example, the linker is one or more amino acid residues positioned between said first peptide and said second peptide. In one example, the linker is at least one amino acid. In one example, the linker is at least two amino acids. In one example, the linker is at least three amino acids. In one example, the linker is four or more amino acids. In one example, the amino acids within the linker may be the same or different.

[0087] In one example, the linker is GlyGly (GG).

[0088] The term "MrgX2 agonist" as used herein refers to an agonist of the MrgX2 receptor.

[0089] The term "agonist" or "receptor agonist" refers to a type of ligand or drug or compound that binds and alters the activity of a receptor. The ability to alter the activity of a receptor, also known as the agonist's efficacy, is a property that distinguishes it from antagonists, a type of receptor ligand which also binds a receptor but which does not alter

the activity of the receptor. The efficacy of an agonist may be positive, causing an increase in the receptor's activity or negative causing a decrease in the receptor's activity.

[0090] In a specific example, the MrgX2 agonist comprises a PAMP12 peptide (FRKKWKNWALSR) (SEQ ID NO: 3).

5 **[0091]** In a specific example, the bioactive self-assembling peptide is (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2).

[0092] In one example, the MrgX2 agonist is useful for activation of mast cells.

[0093] The term "mast cell" refers to a granulocyte that contains granules. In some embodiments, the term "mast cell" refers to a mastocyte. In some embodiments, the term "mast cell" refers to a labrocyte. In some embodiments, the term "mast cell" refers to a leukocyte. In some embodiments, the term "mast cell" refers to an inactivated mast cell. In some embodiments the term "mast cell" refers to an activated mast cell. In some embodiments, the term "mast cell" refers to a mast cell residing in the bone marrow, in the systemic circulatory system, and/or in organ tissues. In some
10
15
embodiments, the organ tissue is the lung, the skin, the heart, the brain, the eye, the gastrointestinal tract, the thymus, the spleen, the ear, the nose or combinations thereof.

[0094] The term "degranulation" of mast cells refers to a cellular process that releases antimicrobial and/or cytotoxic molecules from secretory vesicles (also referred to as granules) found in mast cells.

20 **[0095]** In one example, the degranulation activity increased proportionally with the increase in (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) from 2.5 to 20% w/w, and the degranulation activity at 20% and 40 % w/w of (RADA)₄-(PAMP-12) (SEQ ID NO: 2).

[0096] Although best known for their role in allergy and anaphylaxis, mast cells play an important protective role as well, being intimately involved in defense against
25
pathogens, such as bacteria.

[0097] Accordingly, activation of mast cells may be used in the treatment of bacterial infection.

[0098] In some examples, mast cells may be used in the treatment of a wound.

[0099] Accordingly, activation may be used in the treatment of wounds in a
30
subject.

[00100] As used herein, "wound" refers broadly to injuries to an organ or tissue of an subject that typically involves division of tissue or rupture of a membrane (e.g., skin), due to external violence, a mechanical agency, or infectious disease.

[00101] A wound can be an epithelial, endothelial, connective tissue, ocular, or any other kind of wound in which the strength and/or integrity of a tissue has been reduced, e.g. trauma has caused damage to the tissue.

[00102] The term "wound" encompasses injuries including, but not limited to, lacerations, abrasions, avulsions, cuts, burns, velocity wounds (e.g., gunshot wounds), penetration wounds, puncture wounds, contusions, diabetic wounds, hematomas, tearing wounds, and/or crushing injuries.

[00103] In one example, the term "wound" refers to an injury to the skin and subcutaneous tissue initiated in any one of a variety of ways (e.g., pressure sores from extended bed rest, wounds induced by trauma, cuts, ulcers, burns and the like) and with varying characteristics.

[00104] As used herein, the term "wound healing" refers to a process by which the body of a wounded subject initiates repair of a tissue at the wound site (e.g., skin).

[00105] Wound healing can be measured by assessing such parameters as contraction, area of the wound, percent closure, percent closure rate, and/or infiltration of blood vessels as known to those of skill in the art.

[00106] In some examples, the self-assembling peptides, nanofibers, and hydrogels, are used to treat a wound in a subject.

[00107] In some examples, the self-assembling peptides, nanofibers, and hydrogels, are used to promote wound healing in a subject.

[00108] The terms "treat" and "treatment" refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or decrease an undesired physiological change or disorder, such as a bacterial infection. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[00109] In one example treatment is *in vitro* treatment. In one example, treatment is *in vivo* treatment.

[00110] As used herein, the term "infection" refers to any state in at least one cell, for example a cell of a subject, is infected by an infectious agent, such as a bacterium or bacteria

[00111] As referred to herein, the term "bacteria" refers to members of a large domain of prokaryotic microorganisms.

[00112] In some examples, the bacteria comprise gram-negative bacteria.

[00113] In some examples, the bacteria comprise gram-positive bacteria.

[00114] Bacteria may be antibiotic-sensitive or an antibiotic-resistant.

[00115] As used herein, the term "bacteria" (and derivatives thereof, such as "microbial infection") includes, but is not limited to, references to organisms (or infections due to organisms) of the following classes and specific types: Gram-positive cocci, such as Staphylococci (e.g. Staph. aureus, Staph. epidermidis, Staph. saprophyticus, Staph. auricularis, Staph. capitis capitis, Staph. c. ureolyticus, Staph. caprae, Staph. cohnii cohnii, Staph. c. ureolyticus, Staph. equorum, Staph. gallinarum, Staph. haemolyticus, Staph. hominis hominis, Staph. h. novobioceticus, Staph. hyicus, Staph. intermedius, Staph. lugdunensis, Staph. pasteurii, Staph. saccharolyticus, Staph. schleiferi schleiferi, Staph. s. coagulans, Staph. sciuri, Staph. simulans, Staph. warneri and Staph. xylosum); Streptococci (e.g. beta-haemolytic, pyogenic streptococci (such as Strept. agalactiae, Strept. canis, Strept. dysgalactiae dysgalactiae, Strept. dysgalactiae equisimilis, Strept. equi equi, Strept. equi zooepidemicus, Strept. iniae, Strept. porcinus and Strept. pyogenes), microaerophilic, pyogenic streptococci (Streptococcus "milleri", such as Strept. anginosus, Strept. constellatus constellatus, Strept. constellatus pharyngidis and Strept. intermedius), oral streptococci of the "mitis" (alpha-haemolytic - Streptococcus "viridans", such as Strept. mitis, Strept. oralis, Strept. sanguinis, Strept. cristatus, Strept. gordonii and Strept. parasanguinis), "salivarius" (non-haemolytic, such as Strept. salivarius and Strept. vestibularis) and "mutans" (tooth- surface streptococci, such as Strept. criceti, Strept. mutans, Strept. rattus and Strept. sobrinus) groups, Strept. acidominimus, Strept. bovis, Strept. faecalis, Strept. equinus, Strept. pneumoniae and Strept. suis, or Streptococci alternatively classified as Group A, B, C, D, E, G, L, P, U or V Streptococcus); Gram-negative cocci, such as Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria cinerea, Neisseria elongata, Neisseria flavescens, Neisseria lactamica, Neisseria mucosa, Neisseria sicca, Neisseria subflava and Neisseria weaveri; Bacillaceae, such as Bacillus anthracis, Bacillus subtilis, Bacillus thuringiensis, Bacillus stearothermophilus and Bacillus cereus; Enterobacteriaceae, such as Escherichia coli, Enterobacter (e.g. Enterobacter aerogenes, Enterobacter agglomerans and Enterobacter

- 12 -

Mycobacterium chubense, Mycobacterium confluentis, Mycobacterium conspicuum,
 Mycobacterium cookii, Mycobacterium flavescens, Mycobacterium gadium,
 Mycobacterium gastri, Mycobacterium genavense, Mycobacterium gordonae,
 Mycobacterium goodii, Mycobacterium haemophilium, Mycobacterium hassicum,
 5 Mycobacterium intracellulare, Mycobacterium interjectum, Mycobacterium heideiberense,
 Mycobacterium lentificum, Mycobacterium maimonense, Mycobacterium microgenum,
 Mycobacterium microti, Mycobacterium mucogenicum, Mycobacterium neoaurum,
 Mycobacterium nonchromogenicum, Mycobacterium peregrinum, Mycobacterium phlei,
 Mycobacterium scrofulaceum, Mycobacterium shimoidei, Mycobacterium simiae,
 10 Mycobacterium szulgai, Mycobacterium terrae, Mycobacterium thermoresistibile,
 Mycobacterium triplex, Mycobacterium triviale, Mycobacterium tusciae, Mycobacterium
 ulcerans, Mycobacterium vaccae, Mycobacterium wolinskyi and Mycobacterium xenopi);
 Haemophilus (e.g. Haemophilus influenzae, Haemophilus ducreyi, Haemophilus
 aegyptius, Haemophilus parainfluenzae, Haemophilus haemolyticus and Haemophilus
 15 parahaemolyticus); Actinobacillus (e.g. Actinobacillus actinomycetemcomitans,
 Actinobacillus equii, Actinobacillus hominis, Actinobacillus lignieresii, Actinobacillus suis
 and Actinobacillus ureae); Actinomyces (e.g. Actinomyces israelii); Brucella (e.g.
 Brucella abortus, Brucella canis, Brucella melitensis and Brucella suis); Campylobacter
 (e.g. Campylobacter jejuni, Campylobacter coli, Campylobacter lari and Campylobacter
 20 fetus); Listeria monocytogenes; Vibrio (e.g. Vibrio cholerae and Vibrio parahaemolyticus,
 Vibrio alginolyticus, Vibrio carchariae, Vibrio fluvialis, Vibrio furnissii, Vibrio hollisae, Vibrio
 metschnikovii, Vibrio mimicus and Vibrio vulnificus); Erysipelothrix rhusopathiae;
 Corynebacteriaceae (e.g. Corynebacterium diphtheriae, Corynebacterium jeikeum and
 Corynebacterium urealyticum); Spirochaetaceae, such as Borrelia (e.g. Borrelia
 25 recurrentis, Borrelia burgdorferi, Borrelia afzelii, Borrelia andersonii, Borrelia bissettii,
 Borrelia garinii, Borrelia japonica, Borrelia lusitanae, Borrelia tanukii, Borrelia turdi,
 Borrelia valaisiana, Borrelia caucasica, Borrelia crocidurae, Borrelia duttoni, Borrelia
 garinoni, Borrelia hermsii, Borrelia hispanica, Borrelia iatyschewii, Borrelia mazzottii,
 Borrelia parkeri, Borrelia persica, Borrelia turicatae and Borrelia venezuelensis) and
 30 Treponema (Treponema pallidum ssp. pallidum, Treponema pallidum ssp. endemicum,
 Treponema pallidum ssp. pertenue and Treponema carateum); Pasteurella (e.g.
 Pasteurella aerogenes, Pasteurella bettyae, Pasteurella canis, Pasteurella dagmatis,
 Pasteurella gallinarum, Pasteurella haemolytica, Pasteurella multocida multocida,
 Pasteurella multocida gallinacea, Pasteurella multocida septicum, Pasteurella pneumotropica
 35 and Pasteurella stomatis); Bordetella (e.g. Bordetella bronchiseptica, Bordetella hinzii,

Bordetella hoimseii, *Bordetella parapertussis*, *Bordetella pertussis* and *Bordetella trematum*); *Nocardiaceae*, such as *Nocardia* (e.g. *Nocardia asteroides* and *Nocardia brasiliensis*); *Rickettsia* (e.g. *Rickettsia* or *Coxiella burnetii*); *Legionella* (e.g. *Legionella anisa*, *Legionella birminghamensis*, *Legionella bozemanii*, *Legionella cinchonae*,
5 *Legionella dumoffii*, *Legionella feeleii*, *Legionella gormanii*, *Legionella hackeliae*, *Legionella israelensis*, *Legionella jordanis*, *Legionella lansingensis*, *Legionella longbeachae*, *Legionella maceachernii*, *Legionella micdadei*, *Legionella oakridgensis*, *Legionella pneumophila*, *Legionella saintelensis*, *Legionella tucsonensis* and *Legionella wadsworthii*); *Moraxella catarrhalis*; *Cyclospora cayentanensis*; *Entamoeba histolytica*;
10 *Giardia lamblia*; *Trichomonas vaginalis*; *Toxoplasma gondii*; *Stenotrophomonas maitrophila*; *Burkholderia cepacia*; *Burkholderia mallei* and *Burkholderia pseudomallei*; *Francisella tularensis*; *Gardnerella* (e.g. *Gardnerella vaginalis* and *Gardnerella mobiliuncus*); *Streptobacillus moniliformis*; *Fiavobacteriaceae*, such as *Capnocytophaga* (e.g. *Capnocytophaga canimorsus*, *Capnocytophaga cynodegmi*, *Capnocytophaga*
15 *gingivalis*, *Capnocytophaga granulosa*, *Capnocytophaga haemolytica*, *Capnocytophaga ochracea* and *Capnocytophaga sputigena*); *Bartonella* (*Bartonella bacilliformis*, *Bartonella clarridgeiae*, *Bartonella elizabethae*, *Bartonella henselae*, *Bartonella quintana* and *Bartonella vinsonii arupensis*); *Leptospira* (e.g. *Leptospira biflexa*, *Leptospira borgpetersenii*, *Leptospira inadai*, *Leptospira interrogans*, *Leptospira kirschneri*,
20 *Leptospira noguchii*, *Leptospira santarosai* and *Leptospira weilii*); *Spirillum* (e.g. *Spirillum minus*); *Bacteroides* (e.g. *Bacteroides caccae*, *Bacteroides capillosus*, *Bacteroides coagulans*, *Bacteroides distasonis*, *Bacteroides eggerthii*, *Bacteroides forsythus*, *Bacteroides fragilis*, *Bacteroides merdae*, *Bacteroides ovatus*, *Bacteroides putredinis*, *Bacteroides pyogenes*, *Bacteroides spianchiticus*, *Bacteroides stercoris*,
25 *Bacteroides tectus*, *Bacteroides thetaiotaomicron*, *Bacteroides uniformis*, *Bacteroides ureolyticus* and *Bacteroides vulgatus*); *Prevotella* (e.g. *Prevotella bivia*, *Prevotella buccae*, *Prevotella corporis*, *Prevotella dentalis* (*Mitsuokella dentalis*), *Prevotella denticola*, *Prevotella disiens*, *Prevotella enoeca*, *Prevotella heparinolytica*, *Prevotella intermedia*, *Prevotella loeschii*, *Prevotella melaninogenica*, *Prevotella nigrescens*,
30 *Prevotella oralis*, *Prevotella oris*, *Prevotella ouivera*, *Prevotella tannerae*, *Prevotella venoralis* and *Prevotella zooglyphiformans*); *Porphyromonas* (e.g. *Porphyromonas asaccharolytica*, *Porphyromonas gingivalis*, *Porphyromonas canis*, *Porphyromonas canis*, *Porphyromonas catoniae*, *Porphyromonas circumdentaria*, *Porphyromonas crevicularis*, *Porphyromonas endodontalis*, *Porphyromonas gingivalis*, *Porphyromonas*
35 *gingivicanis*, *Porphyromonas ivorii* and *Porphyromonas macacae*); *Fusobacterium* (e.g. *F.*

gonadiaformans, *F. mortiferum*, *F. naviforme*, *F. necrogenes*, *F. necrophorum*
necrophorum, *F. necrophorum fundiliforme*, *F. nucleatum nucleatum*, *F. nucleatum*
fusiforme, *F. nucleatum polymorphum*, *F. nucleatum vincentii*, *F. periodontium*, *F. russii*,
F. uicerans and *F. varium*); Chlamydia (e.g. Chlamydia trachomatis); Cryptosporidium
5 (e.g. *C. parvum*, *C. hominis*, *C. canis*, *C. felis*, *C. meleagridis* and *C. muris*);
Chlamydophila (e.g. Chlamydophila abortus {Chlamydia psittaci}, Chlamydophila
pneumoniae {Chlamydia pneumoniae} and Chlamydophila psittaci {Chlamydia psittaci});
Leuconostoc (e.g. Leuconostoc citreum, Leuconostoc cremoris, Leuconostoc
dextranicum, Leuconostoc iactis, Leuconostoc mesenteroides and Leuconostoc
10 pseudomesenteroides); Gemeiia (e.g. Gemeiia bergeri, Gemeiia haemolyans, Gemeiia
morbillorum and Gemeiia sanguinis); and Ureaplasma (e.g. Ureaplasma parvum and
Ureaplasma urealyticum).

[00116] An infection may also refer to the presence of more than one type of
bacteria, in or on a subject. For example, the bacterial infection may be caused by a
15 mixture of Gram-positive bacteria, by a mixture of Gram-negative bacteria or by a mixture
of both Gram-positive and Gram-negative bacteria. An infection may also be caused, for
example, by a mixture of aerobic bacteria, anaerobic bacteria or both.

[00117] In use, in one example, a hydrogel is formed with a bioactive self-
assembling peptide.

20 **[00118]** The term “hydrogel” as used herein refers to a polymeric material that
exhibits the ability to swell in a liquid and retain a significant portion of liquid within its
structure without dissolution. In some examples, the liquid is a pharmaceutically
acceptable solvent, such as water or phosphate buffered saline, which should not
interfere with the biological activity of the bioactive self-assembling peptide.

25 **[00119]** In one example, the hydrogel comprises the bioactive self-assembling
peptide as described herein. In another example, the hydrogel comprises a bioactive
self-assembling peptide as described herein and a self-assembling peptide.

[00120] In some examples, the hydrogel comprises about 20 to about 100% (w/v)
of the bioactive self-assembling peptide.

30 **[00121]** In one example, the hydrogel comprises about 20% w/w (RADA)₄-GG-
(PAMP-12) (SEQ ID NO: 2). In one example, the hydrogel comprises more than 20%
w/w (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2).

[00122] In a specific example, the bioactive self-assembling peptide is (RADA)₄-
GG-PAMP12 (SEQ ID NO: 2), and the self-assembling peptide is (RADA)₄ (SEQ ID NO:
35 1). In one example, the hydrogel comprises about 20% w/w (RADA)₄-GG-(PAMP-12)

(SEQ ID NO: 2). In one example, the hydrogel comprises more than 20% w/w (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2).

[00123] In some examples, the self-assembling peptides, nanofibers, and hydrogels, are pharmaceutically acceptable.

5 **[00124]** The term pharmaceutically acceptable refers to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, diluent,
10 excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

[00125] The hydrogel is administered to a subject for the treatment of a bacterial infection.

[00126] The hydrogel may be administered alone or in combination with other
15 treatments, either simultaneously or sequentially, dependent upon the condition to be treated.

[00127] In treating a subject, a therapeutically effective amount of a bioactive self-assembling peptide may be administered to the subject.

[00128] The term "therapeutically effective amount" or "effective amount" is an
20 amount sufficient to effect beneficial or desired clinical results. An effective amount can be administered in one or more administrations.

[00129] The compounds and compositions may be administered to a subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g.
25 transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an aerosol, e.g. through mouth or nose); rectal; vaginal; parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and
30 intrasternal; by implant of a depot / for example, subcutaneously or intramuscularly.

[00130] In some examples, the bioactive-self assembling peptide may be lyophilized.

[00131] In some examples, the bioactive-self assembling peptide may be formulated for presentation in unit-dose or multi-dose containers, for example sealed
35 ampoules and vials, and may be stored in lyophilized condition. In some examples,

extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

[00132] In some examples, a lyophilized bioactive-self assembling peptide may be incorporated in to a bandage, and/or dressing, and/or, or other application device.

5 **[00133]** The term “bandage” and “dressing” are used to refer to a piece of material that is in direct contact with a wound, and may be used to promote healing and/or prevent further harm. Bandages are available in a wide range of types, from generic cloth strips, to specialized shaped bandages designed for a specific limb or part of the body, although bandages can often be improvised as the situation demands, using clothing, blankets or
10 other material. Accordingly, bandages and dressing include, but are not limited to, wrappable lengths, patches, plasters, compresses.

[00134] In some examples, the bioactive self-assembling peptide, nanofibers, or hydrogels, disclosed herein may be used in the methods described herein in combination with standard treatment regimes, as would be known to the skilled worker.

15 **[00135]** For example, common drugs and/or combinations of such drugs used in the treatment of a bacterial infection include, but are not limited to, antimicrobial agents.

[00136] The term “antimicrobial agent” as used herein refers to any entity with antimicrobial activity. In some examples, the antimicrobial agent inhibits or reduces the growth and/or kills a microbe, such as bacteria.

20 **[00137]** An antimicrobial agent can be, for example, but not limited to, a small molecule, a peptide, a peptidomimetic, an antibody or a fragment thereof, a nucleic acid, an enzyme, an aptamer,

[00138] Examples of classes of antibiotics include, but are not limited to, β -lactams, including the penicillins, cephalosporins monobactams, methicillin, and
25 carbapenems; aminoglycosides, e.g., gentamicin, kanamycin, neomycin, tobramycin, netilmycin, paromomycin, and amikacin; tetracyclines, e.g., doxycycline, minocycline, oxytetracycline, tetracycline, and demeclocycline; sulfonamides (e.g., mafenide, sulfacetamide, sulfadiazine and sulfasalazine) and trimethoprim; quinolones, e.g., ciprofloxacin, norfloxacin, and ofloxacin; glycopeptides (e.g., vancomycin, telavancin,
30 teicoplanin); macrolides, which include for example, erythromycin, azithromycin, and clarithromycin; carbapenems (e.g., ertapenem, doripenem, meropenem, and imipenem); cephalosporins (e.g., cefadroxil, cefepime, and ceftobiprole); lincosamides (e.g., clindamycin, and lincomycin); monobactams (e.g., aztreonam); nitrofurans (e.g., furazolidone, and nitrofurantoin); (13) Penicillins (e.g., amoxicillin, and Penicillin G);
35 polypeptides (e.g., bacitracin, colistin, and polymyxin B); and other antibiotics, e.g.,

ansamycins, polymycins, carbacephem, chloramphenicol, lipopeptide, and drugs against mycobacteria (e.g., the ones causing diseases in mammals, including tuberculosis (*Mycobacterium tuberculosis*) and leprosy (*Mycobacterium leprae*), and any combinations thereof.

5 **[00139]** Method of the invention are conveniently practiced by providing the compounds and/or compositions used in such method in the form of a kit. Such kit preferably contains the composition. Such a kit preferably contains instructions for the use thereof.

10 **[00140]** To gain a better understanding of the invention described herein, the following examples are set forth. It should be understood that these examples are for illustrative purposes only. Therefore, they should not limit the scope of this invention in anyway.

[00141] EXAMPLES

15 **[00142]** Traditionally, mast cells are best known for their important role in allergic inflammatory responses, however, mast cells also participate in protective actions such as wound healing, angiogenesis and host defense against pathogens and animal venoms [1-5]. Mature mast cells are distributed widely in connective tissues that interface with the external environment throughout the body: skin, digestive tract, mucosa of lung and airways, etc. [6, 7]. These cells contain a number of secretory granules, which are filled
20 with a large amount of pre-formed and pre-activated compounds like histamine, heparin and serine proteases, cytokines and growth factors [1, 8]. Upon stimulation, mast cell degranulation occurs and leads to the rapid release of pre-stored and neo-synthesized mediators. Therefore, mast cells can be considered as the first responders that play a critical role in both host defense and tissue repair.

25 **[00143]** Many mediators produced by mast cells have direct anti-microbial activity. Anti-microbial peptides expressed by mammalian mast cells, known as cathelicidins, play a key role in innate immune defense against invasive bacterial infection [9]. Some studies have indicated the potential applications of harnessing mast cell mediated host defense for bacterial infections. For example, the cathelicidin peptide LL-37 released from mast
30 cells during degranulation have a potent antimicrobial effect against the multidrug-resistant bacteria *Enterococcus faecalis* [10], and provide protection against necrotic skin infection caused by Group A Streptococcus [11].

35 **[00144]** Mast cells produce a large variety of pro-angiogenic factors, including prestored and de novo expressed vascular endothelial growth factor (VEGF) upon activation. It was reported that low dose irradiation increases VEGF production by mast

cells and promotes vascular regeneration in an ischemic model [12]. Additionally, mast cells release preformed fibroblast growth factor (FGF)-2 from their secretory granules upon stimulation, which promote angiogenesis during chronic inflammation [13]. The intraperitoneal injection of stimulus compound 48/80 causes a vigorous angiogenic response in rat and mice tissue [14, 15]. In addition, mast cell proteases, tryptase and chymase, are directly involved in angiogenesis [16, 17].

[00145] Wound healing is a dynamic process that involves in inflammation, tissue regeneration and remodeling, and mast cell play an important role in it. During skin wound healing, mast cells can interact with macrophages, endothelial cells, and fibroblasts, and promote tissue granulation, cell migration, angiogenesis, and collagen maturation through the releasing of interleukin-4 (IL-4), VEGF, bFGF, chymase, and typtase, etc., into the local microenvironment [18-25]. It has been reported that anti-microbial peptides, LL-37, β -defensin 3, retrocyclin and protegrin activate mast cell was described as a therapeutic potential in wound healing [26-28]. Recently, similar result has been described in a mice diabetes model that substance P stimulation improves skin wound healing in wild-type, but not mast cell deficient mice, implying the mast cells is required for proper wound healing and the therapeutic potential of manipulation of mast cell activation at certain site [21]. Another example of phototherapy is that using light-emitting diodes (LEDs) with 830 nm light to initiate dermal mast cell degranulation, which accelerate wound healing process with a controlled inflammatory process and benefit skin rejuvenation [29].

[00146] Recently, scaffolds that interact with the immune system and trigger an immune response in damaged tissue have been shown to be an exciting emerging therapeutic avenue for promoting tissue repair [30-33]. As described, mast cells wildly populate connective tissues such as skin and these cells can rapidly release large amounts of pre-formed granule compounds upon appropriate stimulation. Therefore, being able to specifically activate the immune response of mast cells in a localized manner so as to directly affect wound healing, angiogenesis and a beneficial host defense is a new therapeutic strategy. Classically, mast cells are activated via an antigen-induced IgE (Fc ϵ -RI) receptor cross-linking on the cell membrane, however, human mast cells can also respond to a series of cationic peptides, including substance P [34-36], vasoactive intestinal peptide (VIP) [35], cortistatin-14 [34-36], LL-37 [37], β -defensins [38] and PAMP-12 [34], etc., through a non-selective cell-membrane receptor, Mas-related G-protein coupled receptor member X2 (MRGPRX2. or MrgX2).

[00147] PAMP-12 (Ac-FRKKWNKWALSR-CONH₂) (SEQ ID NO: 3), or PAMP [9-20] is the C-terminal region of proadrenomedullin N-terminal 20 peptide (PAMP-20, or PAMP [1–20]), a 20-amino acid hypotensive peptide expressed in the adrenal medulla. PAMP-12 (SEQ ID NO: 3) was identified as an endogenous ligand for MRGPRX2, which
 5 induced the activation of mast cells in a dose-dependent manner [34]. This work has shown that the extent of mast cell activation can be controlled by the concentration of bioactive peptides within the tissue. Compared to systemic administration, the localized administration of bioactive peptides at the site of interest can result in reduced side-effects, a greater therapeutic outcome, while using a lower overall amount of peptide
 10 drug.

[00148] Self-assembling peptide based materials are becoming recognized as a robust platform for many tissue engineering applications. They are of particular interest given they are composed of peptides that can be cleared by the host, do not come from animal sources, and allow for the direct implementation of bioactive moieties to induce a
 15 variety of therapeutic functions. The ion-complementary self-assembling peptide, (RADA)₄ (SEQ ID NO: 1), is comprised of alternating hydrophobic and hydrophilic amino acids and has been shown to form well-ordered β -sheet nanofibers that subsequently develop into a highly hydrated (>99.5% water), 3-D hydrogel matrix in physiological solutions [39-46]. One advantage of (RADA)₄ nanoscaffolds is the potential for molecular
 20 level programmability; biofunctionality of the assembled nanomatrix can be introduced by directly extending the self-assembling peptide sequence with bioactive motifs (e.g. cell adhesion,[47] angiogenesis,[48-50] bone regeneration,[51, 52] nerve regeneration,[53, 54] etc.).

[00149] In this work, the dose dependent effect PAMP-12 modified (RADA)₄ (SEQ ID NO: 1) matrix on mast cell degranulation was studied. The activation of mast cells was found to be controllable through varying the amount of PAMP-12 tethered to the nanofiber matrix. Furthermore, through tethering of the PAMP-12 to the self-assembling matrix it was found that only mast cells in direct contact with the matrix were activated; illustrating that cell activation could be controlled locally.

30 [00150] ***Materials and methods***

[00151] ***Materials***

[00152] The PAMP-12 (SEQ ID NO: 3), (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) peptide ($\geq 95\%$ purity) was purchased from RS Synthesis (Louisville, KY, USA), checked for purity using mass spectroscopy and used without
 35 further purification. Endotoxin levels of all peptides were tested using ToxinSensor™

Chromogenic LAL Endotoxin Assay Kit from GenScript (Piscataway, NJ, USA). (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) contained < 0.1 EU/mg endotoxin (e.g. 50 µl of 0.5% w/v nanoscaffold contained < 0.05 EU endotoxin), and the endotoxin levels of PAMP-12 at working concentrations were less than 0.1 EU/ml.

5 (Sensitivity: 0.005 EU/ml, R²=0.9952). The 0.2 µm Anopore® Membrane Nunc Culture Inserts were purchased from Nalge Nunc International (Rochester, NY, USA). The chemical structures of (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) are shown in Fig. 1A-C.

[00153] Hydrogel matrices preparation

10 **[00154]** (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO:2) stock solutions (1.0% w/v) were prepared by dissolving peptide powder in syringe filtered (0.2 µm) Milli-Q water. Peptide stock solutions were sonicated for 30 min to avoid bulk aggregates and reduce viscosity. (RADA)₄ peptide solutions with different proportion of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) (0, 2.5, 5, 10, 20, 40, 80, 100% w/w) were
15 mixed with 1x PBS (pH 7.4) at a ratio of 1:1 (v/v) to get hydrogel matrices with peptide concentration of 0.5% w/v. Fifty µl of the mixture was placed at the bottom of a 96-well plate or well insert, overnight at 4 °C and washed with HEPES buffer (10 mM, with 0.4% BSA, pH 7.4) or PBS for 3 times.

[00155] Atomic force microscopy (AFM)

20 **[00156]** The morphology of the hydrogel matrices were measured using Dimension 3100 Nanoman Atomic Force Microscopy (AFM, Veeco Metrology, LLC) with tapping mode, tip radius of 8 nm. Matrix solutions used in AFM studies were prepared by 500 times diluted with Mili-Q water. A drop (5 ul) of each solution was placed on freshly cleaved mica substrate then rise with water. The surfaces were air dried overnight at
25 room temperature before being imaged.

[00157] Cell Culture

[00158] LAD2 (Laboratory of Allergic Diseases 2) human mast cells were incubated in StemPro-34 SFM medium (Life Technologies, Rockville, MD) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 50 µg/ml streptomycin, 100 ng/ml
30 recombinant human SCF (Peprotech, Rocky Hill, NJ). Cells were maintained at 0.1 ×10⁶ cells/ml at 37 °C and 5% CO₂. Cell suspensions were isolated via centrifugation (200 g, 5 min, at room temperature) and media was replaced every 3-7 days.

[00159] *Evaluation of degranulation using the β -Hexosaminidase (β -hex) release assay*

[00160] For each well, 0.25×10^5 LAD2 cells were washed and resuspended in 90 μ l HEPES buffer (10 mM, with 0.4% BSA, pH 7.4), and activated by adding 10 μ l peptide solutions (PAMP-12 (SEQ ID NO: 2), (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2)) in PBS (1x, pH 7.4) for 30 min at 37 °C, the final concentrations of peptide are 0, 0.01, 0.1, 1, 10, 20, 50, 100 μ M respectively. β -hex release was quantified through analysis of the hydrolysis of p-nitrophenyl N-acetyl- b-D-glucosamide (Sigma Aldrich, Oakville, ON, Canada) in 0.1 M sodium citrate buffer (pH 4.5) for both the supernatant and in total cell lysates solubilized with 0.01% Triton X-100 for 90 min at 37°C. The reaction was stopped by adding glycine buffer (pH 10.7). Read absorbance at 405 nm with reference filter at 620 nm. The percent-age of β -hex released into the supernatant was calculated by the β -hex contents of supernatant and cell lysate.

[00161] To evaluate the effect of the matrices on degranulation, 0.25×10^5 LAD2 cells in 50 μ l HEPES buffer (10 mM, with 0.4% BSA, pH 7.4) were carefully placed on the top of 50 μ l hydrogel matrices, and the β -hex release was measured as described. After 30 min incubation, cell free supernatant and total cells with the matrices were collected by centrifugation (300 g, 5 min) for analysis.

[00162] To evaluate the immobilization effect of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) in the matrices. As shown in Fig. 6 (A), 0.25×10^5 LAD2 cells in 100 μ l HEPES buffer (10 mM, with 0.4% BSA, pH 7.4) were co-incubated with well inserts that contain 50 μ l of self-assembling matrix (20% and 100% w/w of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2)) or PAMP-12 (SEQ ID NO: 3) solution in HEPES buffer (10 mM, with 0.4% BSA, pH 7.4) with the corresponding concentration (0.29 and 1.46 mM respectively). After 30 min incubation, inserts were removed, and the β -hex release was measured as described.

[00163] *Cell viability analysis using XTT assay*

[00164] LAD2 cells were suspended in culture medium (50 μ l, 1.0×10^6 cells/ml) and placed on top of 50 μ l of hydrogel matrix or culture medium solution. After an 4 h or 24 h incubation, cell viability was measured using a 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) proliferation kit (Roche Molecular Biochemicals, Indianapolis, IN, USA), according to the manufacturer's supplied instructions. To facilitate a uniform distribution of color throughout the hydrogel matrix, 50 μ l of DMSO was added into each well prior to analysis.

35

[00165] *Laser-scanning confocal microscopy*

[00166] For each sample, 0.25×10^5 LAD2 cells in 50 μ l culture medium were allowed to incubate with 50 μ l hydrogel matrix for 30 min at 37 °C. After incubation, the medium was disposed, and hydrogel matrix was carefully washed by warm PBS for 3
5 times to remove non-adherent cells. Hydrogel matrices were then fixed in 3.7% paraformaldehyde in PBS for 20 min at room temperature and 3 times washed in PBS. Cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min, washed in PBS for 3 times, then followed by 3% BSA blocking for 30 min and 3 times washing in PBS. To stain F-actin, samples were incubated with 0.5 μ M Phalloidin-FITC (Sigma-Aldrich, USA) for 30
10 minutes and followed by 3 times washing in PBS. Cell nuclei were stained with 1 μ g/mL DAPI (Sigma-Aldrich, USA) in PBS for 30 min. After 3 times washing in PBS, Z-slice images of the matrix with adhered LAD2 cells were collected using Laser Scanning Confocal Microscopy (LSM710, Carl Zeiss AG, Oberkochen, Germany) with an inverted 10x objective.

15 [00167] *Harvesting of human skin tissue*

[00168] Human skin was harvested from abdominoplasty surgical discard specimens obtained following written informed consent as approved by the University of Alberta research ethics board. All tissue was from healthy non-smokers in their 30s.

[00169] *Fluorescent staining of mast cells in human skin*

20 [00170] Human skin biopsies were fixed in 10% formalin for at least 24 h, embedded in paraffin and mounted on glass slides were incubated at 60 °C for 20 min before deparaffinization and rehydration in two changes of xylene and five changes of ethanol in descending concentrations [55]. Sections then underwent heat mediated antigen retrieval in sodium citrate buffer, pH 6.0 in a conventional pressure cooker for
25 approximately 10 min, or just prior to boiling and cooled for 20 min. Image-iT™ RX Signal Enhancer (Thermo Fisher Scientific Inc, Waltham, MA) was used for 30 min to enhance signal and mask autofluorescence, followed by 1 h incubation with 10% goat serum. After washing 3 times for 5 min in PBS, sections were incubated with a 1:500 dilution of an anti-mast cell tryptase primary antibody (ab134932 Abcam, Cambridge, UK) for 16 h at 4
30 °C then washed again. Subsequently slides were incubated with a 1:350 dilution of Alexa Fluor® 546 goat anti-rabbit secondary antibody (Thermo Fisher Scientific Inc, Waltham, MA) for 1.5 h. Washing and mounting of sections with ProLong® Gold Antifade with DAPI (Thermo Fisher Scientific Inc, Waltham, MA) was then performed prior to image analysis. Sections were photographed using NIS Elements Imaging Software on a Nikon Eclipse
35 Ti-E inverted microscope.

[00171] *In vitro activation of mast cells in human skin*

[00172] Human skin was separated from the underlying adipose tissue using a 15 blade scalpel. The epidermis was then removed using a Padgett dermatome (Integra LifeSciences Corporation, Cincinnati, OH) set to 0.25 mm thickness. The deepithelialized dermis was then divided into multiple pieces 1 cm² using sharp surgical scissors. Control or active hydrogel matrix (100 µl) was then layered onto the exposed surface of the dermis. Pieces were then placed with the gel side up in 6 well plates (Corning) with 2 ml of Dulbecco's Modified Eagle Medium (Life) per well, and incubated for 2 h in a cell culture incubator with 5% CO₂, 95% humidity at 37 °C. For some groups, PBS and PAMP-12 PBS solution were used as negative and positive control. Following this, tissue pieces were removed and snap frozen in liquid nitrogen and stored at -80 °C until further processing.

[00173] *Droplet digital PCR (ddPCR) for mast cell tryptase gene (TPSAB1) expression*

[00174] Total RNA was isolated from tissue by placing pieces individually into a high frequency pulverizer which was kept cool with liquid nitrogen, and shaken until all tissue was ground into a fine powder. This powder was then dissolved in Trizol (Life), and mRNA extracted using the manufacturer's standard protocol. cDNA was generated using a reverse transcription kit (Qiagen) using the manufacturer's standard protocol. To obtain the absolute quantity of TPSAB1 transcripts, ddPCR (QX100, Bio-Rad, Hercules, CA) was employed using 5 ng of each cDNA sample and ddPCR supermix for the specific probes (Bio-Rad) according to manufacturer's protocols. The PrimeTime qPCR assays for TPSAB1 (Assay ID, Hs.PT.58.19121290.g), CMA1 (Assay ID, Hs.PT.58.27270145.g) and a reference gene, ACTB (Assay ID, Hs.PT.39a.22214847) were obtained from IDT (Coralville, IA). The ddPCR conditions comprised of an initial denaturation for 10 min at 95 °C followed by 45 cycles of denaturation for 30 s at 94 °C, and annealing and extension for 1 min at 60 °C, and the final extension for 10 min at 98 °C. Template cDNA was omitted from the ddPCR reaction for no template control (NTC). QuantaSoft Software (Bio-Rad) was employed to analyze ddPCR results, and the absolute concentration of TPSAB1 transcripts in each sample determined by ddPCR was divided by the ACTB transcripts and presented as percentage based on normal skin samples (NS average taken as 100).

[00175] *Statistical analysis*

[00176] All data were conducted in at least quadruplicate with independent repeats and presented as average ± standard error of the mean (SEM). The statistical

significance of differences between mean values was determined using one-way ANOVA followed by two-tailed Student's t-test for analysis of variance, where significance was evaluated for $p < 0.05$, $p < 0.01$, $p < 0.001$.

[00177] Results

5 **[00178]** In order to evaluate the self-assembly property of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) peptide, AFM characterization of the (RADA)₄ (SEQ ID NO: 1) matrices with different ratios of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2): (RADA)₄ (SEQ ID NO: 1) was conducted. AFM results for nanofiber matrices are summarized in Fig. 3 (a-f). Pure 0.5% w/v (RADA)₄ (SEQ ID NO: 1) produced the expected long, evenly distributed, nanofibers (Fig. 3a). Upon incorporation of 10% w/w (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) (Fig. 3b), the nanofiber network overall maintained a similar structure as the (RADA)₄ control. However, thick sections were observed within the formed nanofibers that may indicate the presence of the PAMP-12 sequence within the formed nanofibers (see arrow). As the (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) proportion increased to 20% and 40% w/w, longer segments of increased thickness appeared embedded in the nanofibers. Although, shorter nanofibers that less than 200 nm were observed, most of the nanofibers in 20% and 40 % w/w are longer than 500 nm. When the proportion of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) reach 80% w/w, an evenly distributed nanofiber network was observed (Fig. 3e). Those nanofibers were significantly thicker than pure (RADA)₄ nanofibers. The nanostructure formed by pure (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) (Fig. 3f) showed thick and short nanofibers and even small nanoparticles. Most of the nanofibers were less than 500 nm, and the nanoparticles were smaller than 200 nm. It is possible that the observed nanoparticle-structures may actually be nanofiber fragments.

25 **[00179]** AFM cross section heights for pure (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) samples were collected and illustrated in Fig. 3g and h. Each peak could be directly correlated to structures that were crossed by the diagonal white arrows in Fig. 3a and f. The cross-sectional profile of pure (RADA)₄ (SEQ ID NO: 1) samples (Fig. 3g) show nanofiber heights of ~1.5 nm, which can be considered as single nanofiber. However, the profile for nanofibers formed from pure (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) showed dramatic increase in height to 2.5-3.5 nm, which is much larger than the height of (RADA)₄ nanofiber. The difference in cross sectional height for each peptide formed nanofiber can help us to understand the morphology change among matrices with different proportion of peptides.

30

[00180] *Effect of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) on mast cell degranulation*

[00181] To ascertain if PAMP-12 activity was retained upon tethering to the RADA moiety, PAMP-12 (SEQ ID NO: 3), (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) were evaluated to see if they induced human mast cell degranulation using the β -hex release assay. LAD2 cells were stimulated with various concentrations of each peptide. It was observed that (RADA)₄ was not capable of initiating the degranulation of LAD2 cells, however, the peptide stimulus PAMP-12 (SEQ ID NO: 3) and the functionalized (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) induced significant degranulation (e.g. $p < 0.001$ at 10 μ M) compared with PBS and (RADA)₄ solutions in a dose dependent manner. Furthermore, it was observed that the solution free PAMP-12 (SEQ ID NO: 3) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) share a similar potency, plateauing at $\sim 75\%$ β -hex release for a concentration of 10 μ M (Fig. 4). Based upon this, 10 μ M of PAMP-12 was chosen as the positive control for further studies.

[00182] *Hydrogel matrices with (RADA)₄-GG-(PAMP-12) induce mast cell degranulation in a dose dependent manner*

[00183] The PAMP-12 modified nanofiber matrix was able to cause LAD2 degranulation in a concentration dependent manner. Similar to the previous result in Fig. 4, the matrix composed of pure (RADA)₄ (SEQ ID NO: 1) did not induce degranulation and showed no significant difference compared to the negative control (PBS) ($p > 0.05$). The degranulation activity increased proportionally with the increase in (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) from 2.5 to 20% w/w, and the degranulation activity at 20% and 40 % w/w of (RADA)₄-(PAMP-12) ($64.2 \pm 3.4\%$ and $70.2 \pm 7.1\%$, respectively) are statistically similar ($p > 0.05$).

[00184] *Hydrogel matrix with 20% w/w of (RADA)₄-GG-(PAMP-12) induce mast cell degranulation locally.*

[00185] As shown in Fig. 6B, the 0.5% w/v matrix with 20% w/w of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) in insert induced very limited degranulation of LAD2 ($11.1 \pm 1.1\%$), compared with incubating with 0.29 mM PAMP-12 (SEQ ID NO: 3) in insert ($65.4 \pm 2.6\%$). The matrix of 100% w/w (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) induced an obvious degranulation ($59.6 \pm 3.1\%$), however, the activity is still significantly lower than incubating with 1.46 mM PAMP-12 in insert ($69.5 \pm 1.2\%$) ($p < 0.05$).

[00186] *The activation and adhesion of LAD2 cells on the surface of hydrogel matrix*

[00187] LAD2 interactions with the nanofiber matrices were characterized using confocal imaging (Z-slices) and 3D reconstruction using IMARIS 8 software (Fig. 7a and b). Only a very small number of cells were found to be associated, post-wash, with the pure (RADA)₄ matrix after 30 min incubation (Fig. 7a). However, matrices containing 20% w/w (RADA)₄-GG-(PAMP-12) showed a considerable amount of cells retained after washing (Fig. 7b). For both systems, mast cells seemed to be found within the same plane, likely on the surface of the matrix.

[00188] Cytoskeleton reorganization is pivotal for cell morphology changes, adhesion, migration and exocytosis of mast cells during activation [58]. The effect of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) stimulation on actin cytoskeletal organization of these mast cells was further characterized using 2D imaging (Fig. 7 c and d). In mast cells stimulated by (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2), lamellipodia and filopodia were observed in association with the F-actin assemblies at and near the membrane features of the cell periphery (Fig. 7d). However, the F-actin organization of LAD2 cells on pure (RADA)₄ matrix are only observed to be ring shaped, with no obvious lamellipodia and filopodia structures (Fig. 7c). This data seems to suggest that cells retained on the PAMP-12 modified matrix are adhered and not been activated.

[00189] **Cell viability**

[00190] The effect of the hydrogel matrices on mast cell viability was evaluated using a standard XTT viability assay (Fig. 8). LAD2 cells (0.5×10⁶ cells/ml) were incubated in PBS (Control), PAMP-12 (SEQ ID NO: 3) (10 μM), 0.5% w/v hydrogel matrices (pure (RADA)₄ (SEQ ID NO: 1) or with 20% w/w (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2)) for 4 h or 24 h. Results indicate that the PAMP-12 and hydrogel matrices was not cytotoxic to LAD2 cells and had no statistically significant effect on LAD2 proliferation after 24 h incubation.

[00191] **The distribution and activation of mast cells in human skin tissue**

[00192] The distribution of mast cell in human skin tissue was observed by using immunofluorescent staining (Fig. 9a). Tryptase is the most abundant mast cell-specific serine proteinase contained in mast cells granules and has been used as a marker for mast cell activation. [59-61]. Mast cell identification and distribution in fixed tissue has been commonly determined using anti-typtase monoclonal antibody based immunohistochemistry [62, 63]. As shown in Fig. 9a, the tryptase (red) containing mast cells are clearly present and distributed evenly in human skin tissue.

[00193] The mRNA expression of TPSAB1 (tryptase) was used as an indicator of human mast cell activation [64-66]. There is a significant difference (p<0.05) of TPSAB1

expression between normal skin (NS) and normal skin without epidermis (NSE) as illustrated in Fig. 9b. After 4 h treatment with PAMP-12 (SEQ ID NO: 3), the TPSAB1 expression level was significantly increased ($p < 0.001$) compared with untreated NSE. There was no significant different between (RADA)₄ hydrogel matrix treatment and untreated NSE, however, (RADA)₄-GG-(PAMP-12) hydrogel matrix successfully increased the TPSAB1 expression level ($p < 0.05$). Again, it was observed that solution free NSE/PAMP-12 (224.2 ± 9.920) and NSE/(RADA)₄-GG-(PAMP-12) (191.1 ± 12.0) were not significantly different, despite the slight difference in average amounts (Fig. 9b).

[00194] Discussion

[00195] In this study, we investigated the strategy of using the well-known peptide activator of mast cells, PAMP-12, conjugated to a self-assembling peptide matrix so as to determine if it was possible to manipulate the human innate immune response.

[00196] AFM techniques were used to verify the morphologies of matrices of pure and mixtures of (RADA)₄ (SEQ ID NO: 1) and (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) and showed that nanofiber formation still occurred upon addition of the PAMP-12 (SEQ ID NO: 3) sequence. Pure (RADA)₄ (SEQ ID NO: 1) peptide nanofiber presents the expected thin and long nanofibers (Fig. 3a and g), while pure (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) peptide formed thick and short nanofibers (Fig. 3f and h). It was also observed that the nanofibers formed from mixtures consisted of thick (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) and thin (RADA)₄ segments, when (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) proportion increased, the continuous thick pieces appeared (Fig. 3a-f). This is likely due to the longer sequence of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) increasing the fiber diameter. Due to the electrostatic attraction between the various nanofiber constructs and the mica used in AFM studies, it is expected that the lack of any other type of structures means that that these peptides are incorporating into the resultant nanofibers only.

[00197] It has been demonstrated that (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) induced mast cell degranulation in a dose dependent manner, the potency of which was similar to solution free PAMP-12 peptides (Fig. 4). The self-assembling peptide (RADA)₄, by contrast, did not activate human mast cell degranulation, suggesting that the degranulation activity of (RADA)₄-GG-(PAMP-12) was fully attributed to the bioactive PAMP-12 domain. Pure (RADA)₄ matrix was unable to induce LAD2 degranulation, while matrices with (RADA)₄-GG-(PAMP-12) induced mast cell activation significantly, which was proportional to the percent composition of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2).

Where the 0.5% w/v matrix with 20% w/w of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) was able to cause the most degranulation of human mast cell (Fig. 5).

[00198] Cell culture inserts used in Fig. 6 have a porous membrane at the bottom of the insert that separates the two compartments, while allowing for diffusion of molecules smaller than the pore size between compartments. In order to evaluate the immobility of (RADA)₄-GG-(PAMP-12) in matrix, we loaded the 0.5% w/v (RADA)₄-GG-(PAMP-12) matrix (20 % and 100 % w/w) and relative concentration of PAMP-12 solution (0.29 and 1.46 mM) in the 96 well inserts (pore size: 0.2 μm, namely 200 nm), and then incubated with LAD2 cells for 30 min for the degranulation assay (Fig. 6a). The effect of the porous membrane is negligible on the diffusion of molecules from the insert to the cell culture medium as both the 0.5% w/v (RADA)₄ nanofiber matrix has a smaller pore size range (5 – 200 nm) compared to the membrane (200 nm) [56, 57]. Culture results shown in Fig. 6b indicate that the soluble (RADA)₄-GG-(PAMP-12) peptides in 20% w/w of (RADA)₄-GG-(PAMP-12) matrix only slightly induced mast cell degranulation compared with PBS control. This is likely due to the fact that all the PAMP-12 sequences were immobilized within the nanofiber matrix and prevented from diffusing through the porous barrier. The control of PAMP-12 solution (0.29 mM) in the insert significantly induced mast cell degranulation, which is due to the diffusion of small size PAMP-12 into mast cell environment. In contrast, pure (RADA)₄-GG-(PAMP-12) matrix (100% w/w) degranulation percentage was significantly lower than the PAMP-12 control (1.46 mM) (p<0.05), but was still considerable. This is likely due to the fact that, as shown with the AFM results (Fig. 3c), nanofibers formed using 100% (RADA)₄-GG-(PAMP-12) yielded a large proportion of peptide nanofibers shorter than 200 nm (Fig. 3f), thus, those short nanofibers consist of (RADA)₄-GG-(PAMP-12) may diffuse through the membrane, and lead to a great degranulation of mast cell. Whereas, AFM result (Fig. 3c) show that nanofibers doped with with 20% w/w of (RADA)₄-GG-(PAMP-12) mainly consist of long nanofibers, and thus the vast majority of PAMP-12 is tethered to the nanofibers and cannot enter the cell culture compartment directly.

[00199] The interaction between LAD2 cells and the nanofiber matrices after 30 min incubation is summarized in Fig. 7 a and b. Apparently, cell adhesion to the (RADA)₄ matrix was not favoured as most of the LAD2 cells were washed away (Fig. 7a). This may due to the lack of cell binding site on (RADA)₄ nanofiber. However, the surface of hydrogel matrix with 20% w/w of (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) was covered with a large number of cells (Fig. 7b). Obviously the PAMP-12 motif provided a binding domain for these cells on formed nanofibers (Fig. 2). Also the mast cell activation may

enhance the adhesion progress as the activation may contribute to mast cell adhesion to nature ECM proteins [70-75]. The LAD2 cells activation by (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) can be identified by the 2D imaging (Fig. 7d), and cell morphology that included the presence of lamellipodia and filopodia were observed via the structures of F-actin assemblies. This similar result was observed for actin rearrangement during secretagogues (e.g., poly-L-lysine) mediated mast cell activation in previous work [76]. However, the adhered LAD2 cells on pure (RADA)₄ matrix have no obvious lamellipodia and filopodia structures, and presented as typical F-actin rings only (Fig. 7c) confirming a lack of activation. The observation of Fig. 7c and coincides with the reported F-actin organization of resting and activated mast cells [58], and correspond to the results of degranulation test that (RADA)₄ has no effect on mast cell activation but (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) initiate the activation process (Fig. 4 and 5). The interaction between mast cells and artificial ECM is rarely reported. Self-assembling peptides, including (RADA)₄ (SEQ ID NO: 1) have also been used as nanoscaffold for 3D cell culture [56]. Thus, mast cells are not sensitive to (RADA)₄ indicate that (RADA)₄ matrix could be amenable as a matrix for mast cell 3D culture. This is important because immature mast cells are recruited through the circulation and become mature in connective tissues [77], however, currently, most of the mast cell studies are in suspension.

[00200] To investigate the effect of designed hydrogel matrix on mast cells in human skin tissue, the TPSAB1 (tryptase) was used as an indicator of mast cell activation. The quantification of TPSAB1 mRNA levels in human tissue is a convenient method to determine the degree of mast cell activation [64-66]. As the TPSAB1 expression need more than 30 min, the cell viability and proliferation for these times needed to be measured. XTT assay results indicated that both matrices and stimulation has no significant effect on LAD2 cell viability after 24 h (Fig. 8). We also demonstrated that mast cells were distribute evenly in human skin tissue, which was identified by staining preformed tryptase in mast cell granules (Fig. 9a). As shown in Fig. 9b, after 4 h incubation, the gene expression levels between NS and NSE groups have a significant different ($p < 0.05$), this may due to different mast cell distribution in the epidermis, or the mast cell activation during epidermis removing process. The expression levels of NSE/PAMP-12 and NSE/(RADA)₄-GG-(PAMP-12) groups increased significantly ($p < 0.001$ and $p < 0.01$, respectively) compared with NSE group, which indicated the activation of human skin mast cell. Moreover, NSE/(RADA)₄ has no effect on TPSAB1

expression, which corresponded to previous in vitro degranulation tests using LAD2 cells (Fig. 4 and 5) and confocal imaging results (Fig. 7).

[00201] Conclusion

[00202] We developed self-assembling bioactive peptide, (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2), which could activate human mast cells in a dose-dependent manner. The (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2) peptide can self-assembled with (RADA)₄ peptide to form nanofiber matrices with controlled amounts of PAMP-12 modification. The degree of mast cell activation can be manipulated through adjusting the bioactive peptide ratio in the matrix and the bioactive peptide can be anchored in the in situ forming nanofiber matrix, which may benefit the localized stimulation and minimize the potential side effects. The designed hydrogel matrix can successfully activate tissue-resident mast cells in human skin by contact.

[00203] References

- [00204]** [1] S. Wernersson, G. Pejler, Mast cell secretory granules: armed for battle, Nat. Rev. Immunol. 14(7) (2014) 478-494.
- [00205]** [2] C. Noli, A. Miolo, The mast cell in wound healing, Veterinary dermatology 12(6) (2001) 303-313.
- [00206]** [3] K. Norrby, Mast cells and angiogenesis, APMIS 110(5) (2002) 355-371.
- [00207]** [4] F. Féger, S. Varadaradjalou, Z. Gao, S.N. Abraham, M. Arock, The role of mast cells in host defense and their subversion by bacterial pathogens, Trends Immunol. 23(3) (2002) 151-158.
- [00208]** [5] J.H. Kim, Y. Jung, B.-S. Kim, S.H. Kim, Stem cell recruitment and angiogenesis of neuropeptide substance P coupled with self-assembling peptide nanofiber in a mouse hind limb ischemia model, Biomaterials 34(6) (2013) 1657-1668.
- [00209]** [6] Y. Kitamura, Heterogeneity of mast cells and phenotypic change between subpopulations, Annu. Rev. Immunol. 7(1) (1989) 59-76.
- [00210]** [7] S.J. Galli, S. Nakae, M. Tsai, Mast cells in the development of adaptive immune responses, Nat. Immunol. 6(2) (2005) 135-142.
- [00211]** [8] A. Grützkau, S. Krüger-Krasagakes, H. Baumeister, C. Schwarz, H. Kögel, P. Welker, U. Lippert, B.M. Henz, A. Möller, Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206, Mol. Biol. Cell 9(4) (1998) 875-884.
- [00212]** [9] M. Zanetti, Cathelicidins, multifunctional peptides of the innate immunity, J. Leukoc. Biol. 75(1) (2004) 39-48.

- [00213]** [10] M. Scheb-Wetzel, M. Rohde, A. Bravo, O. Goldmann, New insights into the antimicrobial effect of mast cells against *Enterococcus faecalis*, *Infect. Immun.* 82(11) (2014) 4496-4507.
- [00214]** [11] V. Nizet, T. Ohtake, X. Lauth, J. Trowbridge, J. Rudisill, R.A. Dorschner, V. Pestonjamas, J. Piraino, K. Huttner, R.L. Gallo, Innate antimicrobial peptide protects the skin from invasive bacterial infection, *Nature* 414(6862) (2001) 454-457.
- [00215]** [12] B. Heissig, S. Rafii, H. Akiyama, Y. Ohki, Y. Sato, T. Rafael, Z. Zhu, D.J. Hicklin, K. Okumura, H. Ogawa, Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization, *The Journal of experimental medicine* 202(6) (2005) 739-750.
- [00216]** [13] Z. Qu, J.M. Liebler, M.R. Powers, T. Galey, P. Ahmadi, X.-N. Huang, J.C. Ansel, J.H. Butterfield, S.R. Planck, J.T. Rosenbaum, Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma, *The American journal of pathology* 147(3) (1995) 564.
- [00217]** [14] K. Norrby, A. Jakobsson, J. Sörbo, Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery, *Virchows Archiv B* 52(1) (1986) 195-206.
- [00218]** [15] K. Norrby, A. Jakobsson, J. Sörbo, Mast-cell secretion and angiogenesis, a quantitative study in rats and mice, *Virchows Archiv B* 57(1) (1989) 251-256.
- [00219]** [16] D. Ribatti, G. Ranieri, Tryptase, a novel angiogenic factor stored in mast cell granules, *Exp. Cell Res.* 332(2) (2015) 157-162.
- [00220]** [17] M. Muramatsu, J. Katada, M. Hattori, I. Hayashi, M. Majima, Chymase mediates mast cell-induced angiogenesis in hamster sponge granulomas, *Eur. J. Pharmacol.* 402(1) (2000) 181-191.
- [00221]** [18] A. Trautmann, G. Krohne, E.-B. Bröcker, C.E. Klein, Human mast cells augment fibroblast proliferation by heterotypic cell-cell adhesion and action of IL-4, *The Journal of Immunology* 160(10) (1998) 5053-5057.
- [00222]** [19] Z. Qu, X. Huang, P. Ahmadi, P. Stenberg, J.M. Liebler, A.-C. Le, S.R. Planck, J.T. Rosenbaum, Synthesis of Basic Fibroblast Growth Factor by Murine Mast Cells Regulation by Transforming Growth Factor Beta, Tumor Necrosis Factor Alpha, and Stem Cell Factor, *Int. Arch. Allergy Appl. Immunol.* 115(1) (1997) 47-54.

- [00223]** [20] M. Artuc, B. Hermes, U. Stckelings, A. Grützkau, B. Henz, Mast cells and their mediators in cutaneous wound healing—active participants or innocent bystanders?, *Exp. Dermatol.* 8(1) (1999) 1-16.
- [00224]** [21] A. Tellechea, E.C. Leal, A. Kafanas, M.E. Auster, S. Kuchibhotla, Y. Ostrovsky, F. Tecilazich, D. Baltzis, Y. Zheng, E. Carvalho, Mast Cells Regulate Wound Healing in Diabetes, *Diabetes* (2016) db150340.
- [00225]** [22] N. Shiota, Y. Nishikori, E. Kakizoe, K. Shimoura, T. Niibayashi, C. Shimbori, T. Tanaka, H. Okunishi, Pathophysiological role of skin mast cells in wound healing after scald injury: study with mast cell-deficient W/W^v mice, *Int. Arch. Allergy Appl. Immunol.* 151(1) (2009) 80-88.
- [00226]** [23] B.C. Wulff, T.A. Wilgus, Mast cell activity in the healing wound: more than meets the eye?, *Exp. Dermatol.* 22(8) (2013) 507-510.
- [00227]** [24] J. Gailit, M.J. Marchese, R.R. Kew, B.L. Gruber, The differentiation and function of myofibroblasts is regulated by mast cell mediators, *J. Invest. Dermatol.* 117(5) (2001) 1113-1119.
- [00228]** [25] J. Douaiher, J. Succar, L. Lancerotto, M.F. Gurish, D.P. Orgill, M.J. Hamilton, S.A. Krilis, R.L. Stevens, Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing, *Adv. Immunol.* 122 (2014) 211.
- [00229]** [26] T. Hirsch, M. Spielmann, B. Zuhaili, M. Fossum, M. Metzsig, T. Koehler, H.U. Steinau, F. Yao, A.B. Onderdonk, L. Steinstraesser, Human beta-defensin-3 promotes wound healing in infected diabetic wounds, *The journal of gene medicine* 11(3) (2009) 220-228.
- [00230]** [27] A.J. Duplantier, M.L. Van Hoek, The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds, *Frontiers in immunology* 4 (2013) 143.
- [00231]** [28] K. Gupta, A. Kotian, H. Subramanian, H. Daniell, H. Ali, Activation of human mast cells by retrocyclin and protegrin highlight their immunomodulatory and antimicrobial properties, *Oncotarget* 6(30) (2015) 28573.
- [00232]** [29] R.G. Calderhead, J. Kubota, M.A. Trelles, T. Ohshiro, One mechanism behind LED phototherapy for wound healing and skin rejuvenation: key role of the mast cell, *Laser Ther.* 17(3) (2008) 141-148.
- [00233]** [30] K. Sadtler, A. Singh, M.T. Wolf, X. Wang, D.M. Pardoll, J.H. Elisseeff, Design, clinical translation and immunological response of biomaterials in regenerative medicine, *Nature Reviews Materials* 1 (2016) 16040.

- [00234] [31] K. Sadtler, K. Estrellas, B.W. Allen, M.T. Wolf, H. Fan, A.J. Tam, C.H. Patel, B.S. Lubner, H. Wang, K.R. Wagner, Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells, *Science* 352(6283) (2016) 366-370.
- [00235] [32] S.F. Badylak, A scaffold immune microenvironment, *Science* 352(6283) (2016) 298-298.
- [00236] [33] Y. Vigneswaran, H. Han, R. De Loera, Y. Wen, X. Zhang, T. Sun, C. Mora-Solano, J.H. Collier, Peptide biomaterials raising adaptive immune responses in wound healing contexts, *Journal of Biomedical Materials Research Part A* (2016).
- [00237] [34] B.D. McNeil, P. Pundir, S. Meeker, L. Han, B.J. Udem, M. Kulka, X. Dong, Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions, *Nature* 519(7542) (2015) 237-241.
- [00238] [35] K. Tatemoto, Y. Nozaki, R. Tsuda, S. Konno, K. Tomura, M. Furuno, H. Ogasawara, K. Edamura, H. Takagi, H. Iwamura, Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors, *Biochem. Biophys. Res. Commun.* 349(4) (2006) 1322-1328.
- [00239] [36] N. Robas, E. Mead, M. Fidock, MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion, *J. Biol. Chem.* 278(45) (2003) 44400-44404.
- [00240] [37] H. Subramanian, K. Gupta, Q. Guo, R. Price, H. Ali, Mas-related Gene X2 (MrgX2) Is a Novel G Protein-coupled Receptor for the Antimicrobial Peptide LL-37 in Human Mast Cells RESISTANCE TO RECEPTOR PHOSPHORYLATION, DESENSITIZATION, AND INTERNALIZATION, *J. Biol. Chem.* 286(52) (2011) 44739-44749.
- [00241] [38] H. Subramanian, K. Gupta, D. Lee, A.K. Bayir, H. Ahn, H. Ali, β -Defensins activate human mast cells via Mas-related gene X2, *The Journal of Immunology* 191(1) (2013) 345-352.
- [00242] [39] H. Yokoi, T. Kinoshita, S.G. Zhang, Dynamic reassembly of peptide RADA16 nanofiber scaffold, *P Natl Acad Sci USA* 102(24) (2005) 8414-8419.
- [00243] [40] S.G. Zhang, F. Gelain, X.J. Zhao, Designer self-assembling peptide nanofiber scaffolds for 3D tissue cell cultures, *Semin Cancer Biol* 15(5) (2005) 413-420.
- [00244] [41] S.G. Zhang, Fabrication of novel biomaterials through molecular self-assembly, *Nat Biotechnol* 21(10) (2003) 1171-1178.
- [00245] [42] F. Gelain, L.D. Unsworth, S. Zhang, Slow and sustained release of active cytokines from self-assembling peptide scaffolds, *J. Control. Release* 145(3) (2010) 231-239.

- [00246] [43] S. Koutsopoulos, L.D. Unsworth, Y. Nagai, S. Zhang, Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold, *Proceedings of the National Academy of Sciences* 106(12) (2009) 4623-4628.
- 5 [00247] [44] Y. Nagai, L.D. Unsworth, S. Koutsopoulos, S. Zhang, Slow release of molecules in self-assembling peptide nanofiber scaffold, *J. Control. Release* 115(1) (2006) 18-25.
- [00248] [45] M. Kabiri, I. Bushnak, M.T. McDermot, L.D. Unsworth, Toward a mechanistic understanding of ionic self-complementary peptide self-assembly: role of
10 water molecules and ions, *Biomacromolecules* 14(11) (2013) 3943-3950.
- [00249] [46] A. Saini, K. Koss, L.D. Unsworth, Effect of Peptide Concentration on Water Structure, Morphology, and Thermal Stability of Self-Assembling (RADA) 4 Peptide Matrices, *Journal of Biomaterials and Tissue Engineering* 4(11) (2014) 895-905.
- [00250] [47] S.G. Zhang, Emerging biological materials through molecular self-
15 assembly, *Biotechnol Adv* 20(5-6) (2002) 321-339.
- [00251] [48] X.M. Wang, A. Horii, S.G. Zhang, Designer functionalized self-assembling peptide nanofiber scaffolds for growth, migration, and tubulogenesis of human umbilical vein endothelial cells, *Soft Matter* 4(12) (2008) 2388-2395.
- [00252] [49] X. Liu, X.M. Wang, A. Horii, X.J. Wang, L. Qiao, S.G. Zhang, F.Z. Cui,
20 In vivo studies on angiogenic activity of two designer self-assembling peptide scaffold hydrogels in the chicken embryo chorioallantoic membrane, *Nanoscale* 4(8) (2012) 2720-2727.
- [00253] [50] J.H. Kim, Y. Jung, B.S. Kim, S.H. Kim, Stem cell recruitment and angiogenesis of neuropeptide substance P coupled with self-assembling peptide
25 nanofiber in a mouse hind limb ischemia model, *Biomaterials* 34(6) (2013) 1657-1668.
- [00254] [51] H.T. Pan, S.F. Hao, Q.X. Zheng, J.F. Li, J. Zheng, Z.L. Hu, S.H. Yang, X.D. Guo, Q. Yang, Bone induction by biomimetic PLGA copolymer loaded with a novel synthetic RADA16-P24 peptide in vivo, *Mat Sci Eng C-Mater* 33(6) (2013) 3336-3345.
- [00255] [52] A. Horii, X.M. Wang, F. Gelain, S.G. Zhang, Biological Designer Self-
30 Assembling Peptide Nanofiber Scaffolds Significantly Enhance Osteoblast Proliferation, Differentiation and 3-D Migration, *Plos One* 2(2) (2007).
- [00256] [53] Z.W. Zou, Q.X. Zheng, Y.C. Wu, X.D. Guo, S.H. Yang, J.F. Li, H.T. Pan, Biocompatibility and bioactivity of designer self-assembling nanofiber scaffold containing FGL motif for rat dorsal root ganglion neurons, *J Biomed Mater Res A* 95A(4)
35 (2010) 1125-1131.

- [00257]** [54] Z.W. Zou, T. Liu, J.F. Li, P.D. Li, Q. Ding, G. Peng, Q.X. Zheng, X.L. Zeng, Y.C. Wu, X.D. Guo, Biocompatibility of functionalized designer self-assembling nanofiber scaffolds containing FRM motif for neural stem cells, *J Biomed Mater Res A* 102(5) (2014) 1286-1293.
- 5 **[00258]** [55] J. Wang, J. Ding, H. Jiao, D. Honardoust, M. Momtazi, H.A. Shankowsky, E.E. Tredget, Human hypertrophic scar-like nude mouse model: Characterization of the molecular and cellular biology of the scar process, *Wound Repair Regen.* 19(2) (2011) 274-285.
- [00259]** [56] F. Gelain, A. Horii, S.G. Zhang, Designer self-assembling peptide scaffolds for 3-D tissue cell cultures and regenerative medicine, *Macromolecular Bioscience* 7(5) (2007) 544-551.
- 10 **[00260]** [57] C.A. Hauser, S. Zhang, Designer self-assembling peptide nanofiber biological materials, *Chem. Soc. Rev.* 39(8) (2010) 2780-2790.
- [00261]** [58] P. Dráber, V. Sulimenko, E. Dráberová, Cytoskeleton in mast cell signaling, *Deciphering new molecular mechanisms of mast cell activation* (2014) 34.
- 15 **[00262]** [59] I.T. Harvima, N.M. Schechter, R.J. Harvima, J.E. Fräki, Human skin tryptase: purification, partial characterization and comparison with human lung tryptase, *Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology* 957(1) (1988) 71-80.
- 20 **[00263]** [60] L.B. Schwartz, D.D. Metcalfe, J.S. Miller, H. Earl, T. Sullivan, Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis, *N. Engl. J. Med.* 316(26) (1987) 1622-1626.
- [00264]** [61] S.I. Butrus, K.I. Ochsner, M.B. Abelson, L.B. Schwartz, The level of tryptase in human tears: an indicator of activation of conjunctival mast cells, *Ophthalmology* 97(12) (1990) 1678-1683.
- 25 **[00265]** [62] A.F. Walls, D.B. Jones, J.H. Williams, M.K. Church, S.T. Holgate, Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase, *The Journal of pathology* 162(2) (1990) 119-126.
- 30 **[00266]** [63] L.W. HUNT, T.V. Colby, D.A. WEILER, S. SUR, J.H. Butterfield, Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase, *Mayo Clin. Proc.*, Elsevier, 1992, pp. 941-948.

- [00267] [64] A.L. Christy, M.E. Walker, M.J. Hessner, M.A. Brown, Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE, *J. Autoimmun.* 42 (2013) 50-61.
- 5 [00268] [65] K.S.H. Blatman, N. Gonsalves, I. Hirano, P.J. Bryce, Expression of mast cell-associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy, *The Journal of allergy and clinical immunology* 127(5) (2011) 1307.
- 10 [00269] [66] C.V. Velasquez, A.D. Roman, N.T.P. Lan, N.T. Huy, E.S. Mercado, F.E. Espino, M.L.M. Perez, V.T.Q. Huong, T.T. Thuy, V.D. Tham, Alpha tryptase allele of Tryptase 1 (TPSAB1) gene associated with Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) in Vietnam and Philippines, *Hum. Immunol.* 76(5) (2015) 318-323.
- [00270] [67] A. Schneider, J.A. Garlick, C. Egles, Self-assembling peptide nanofiber scaffolds accelerate wound healing, *PLoS ONE* 3(1) (2008) e1410.
- 15 [00271] [68] H. Meng, L. Chen, Z. Ye, S. Wang, X. Zhao, The effect of a self-assembling peptide nanofiber scaffold (peptide) when used as a wound dressing for the treatment of deep second degree burns in rats, *Journal of Biomedical Materials Research Part B: Applied Biomaterials* 89(2) (2009) 379-391.
- 20 [00272] [69] A. Saini, K. Serrano, K. Koss, L.D. Unsworth, Evaluation of the hemocompatibility and rapid hemostasis of (RADA) 4 peptide-based hydrogels, *Acta Biomater.* (2015).
- [00273] [70] V. Lam, J. Kalesnikoff, C.W. Lee, V. Hernandez-Hansen, B.S. Wilson, J.M. Oliver, G. Krystal, IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE+ antigen but distinct from those used by Steel
- 25 factor, *Blood* 102(4) (2003) 1405-1413.
- [00274] [71] H. Vliagoftis, Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1, *The Journal of immunology* 169(8) (2002) 4551-4558.
- [00275] [72] A. Rosbottom, C.L. Scudamore, H. von der Mark, E.M. Thornton, S.H. Wright, H.R. Miller, TGF- β 1 regulates adhesion of mucosal mast cell homologues to laminin-1 through expression of integrin α 7, *The Journal of Immunology* 169(10) (2002) 5689-5695.
- 30 [00276] [73] J. Dastyh, D.D. Metcalfe, Stem cell factor induces mast cell adhesion to fibronectin, *The Journal of Immunology* 152(1) (1994) 213-219.

[00277] [74] H.L. Thompson, P.D. Burbelo, D.D. Metcalfe, Regulation of adhesion of mouse bone marrow-derived mast cells to laminin, The Journal of Immunology 145(10) (1990) 3425-3431.

[00278] [75] S. Krüger-Krasagakes, A. Grützkau, R. Baghramian, B.M. Henz,
5 Interactions of immature human mast cells with extracellular matrix: expression of specific adhesion receptors and their role in cell binding to matrix proteins, J. Invest. Dermatol. 106(3) (1996) 538-543.

[00279] [76] Z. Deng, T. Zink, H.-y. Chen, D. Walters, F.-t. Liu, G.-y. Liu, Impact of actin rearrangement and degranulation on the membrane structure of primary mast cells:
10 a combined atomic force and laser scanning confocal microscopy investigation, Biophys. J. 96(4) (2009) 1629-1639.

[00280] [77] M.F. Gurish, K.F. Austen, The diverse roles of mast cells, The Journal of experimental medicine 194(1) (2001) F1-F6.

[00281] The embodiments described herein are intended to be examples only.
15 Alterations, modifications and variations can be effected to the particular embodiments by those of skill in the art. The scope of the claims should not be limited by the particular embodiments set forth herein, but should be construed in a manner consistent with the specification as a whole.

[00282] All publications, patents and patent applications mentioned in this
20 Specification are indicative of the level of skill those skilled in the art to which this invention pertains and are herein incorporated by reference to the same extent as if each individual publication patent, or patent application was specifically and individually indicated to be incorporated by reference.

[00283] The invention being thus described, it will be obvious that the same may
25 be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modification as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

WHAT IS CLAIMED IS:


1. A bioactive self-assembling peptide, comprising: a first peptide comprising a self-assembling peptide that mediates self-assembly; and a second peptide comprising a MrgX2 agonist.
2. The bioactive self-assembling peptide of claim 1, further comprising a linker positioned between said first peptide and said second peptide.
3. A bioactive self-assembling peptide, comprising: a first peptide comprising a self-assembling peptide that mediates self-assembly; and a second peptide comprising a MrgX2 agonist; and a linker positioned between said first peptide and said second peptide.
4. The bioactive self-assembling peptide of any preceding claim, wherein said linker comprises a peptide, preferably at least two peptides.
5. The bioactive self-assembling peptide of any preceding claim, wherein said linker comprises the amino acid sequence Gly-Gly.
6. The bioactive self-assembling peptide of any preceding claim, wherein said first peptide comprises the peptide (RADA)₄ (SEQ ID NO: 1).
7. The bioactive self-assembling peptide of any preceding claim, wherein said second peptide comprises PAMP12 (SEQ ID NO: 3).
8. A bioactive self-assembling peptide comprising or consisting of the peptide (RADA)₄-GG-(PAMP-12) (SEQ ID NO: 2).
9. A nanofiber comprising a bioactive self-assembling peptide according to any preceding claim.
10. A hydrogel comprising a bioactive self-assembling peptide according to any one of claims 1 to 9, and a liquid.

11. The hydrogel of claim 10, comprising at least about 20% (w/w) said bioactive self-assembling peptide.
12. A hydrogel comprising a bioactive self-assembling peptide according to any one of claims 1 to 9, a self-assembling peptide, and a liquid.
13. The hydrogel of claim 12, comprising at least about 20%(w/w) said bioactive self-assembling peptide.
14. Use of a bioactive self-assembling peptide according to any one of claims 1 to 9, for activation of a mast cell in a subject.
15. Use of a bioactive self-assembling peptide according to any one of claims 1 to 9, for the treatment of a bacterial infection in a subject.
16. Use of a bioactive self-assembling peptide according to any one of claims 1 to 9, for the treatment of a wound in a subject.
17. Use of a nanofiber of claim 9, for activation of a mast cell in a subject.
18. Use of a nanofiber of claim 9, for the treatment of a bacterial infection in a subject.
19. Use of a nanofiber of claim 9, for the treatment of a wound a subject.
20. Use of a hydrogel of any one of claims 10 to 13, for activation of a mast cell in a subject.
21. Use of a hydrogel of any one of claims 10 to 13, for the treatment of a bacterial infection in a subject.
22. Use of a hydrogel of any one of claims 10 to 13, for the treatment of a wound in a subject.
23. Use of a bioactive self-assembling peptide according to any one of claims 1 to 8, in the manufacture of a medicament for activation of a mast cell in a subject.

24. Use of a bioactive self-assembling peptide according to any one of claims 1 to 8, in the manufacture of a medicament for the treatment of a bacterial infection in a subject.
25. Use of a bioactive self-assembling peptide according to any one of claims 1 to 8, in the manufacture of a medicament for the treatment of a wound in a subject.
26. The use of any one of claims 14 to 25, further comprising use of an antibiotic.
27. Use of a nanofiber of claim 9, in the manufacture of a medicament for activation of a mast cell in a subject.
28. Use of a nanofiber of claim 9, in the manufacture of a medicament for the treatment of a bacterial infection in a subject.
29. Use of a nanofiber of claim 9, in the manufacture of a medicament for the treatment of a wound in a subject.
30. Use of a hydrogel of any one of claims 10 to 13, in the manufacture of a medicament for activation of a mast cell in a subject.
31. Use of a hydrogel of any one of claims 10 to 13, in the manufacture of a medicament for the treatment of a bacterial infection in a subject.
32. Use of a hydrogel of any one of claims 10 to 13, in the manufacture of a medicament for the treatment of a wound a subject.
33. The use of any one of claims 27 to 32, further comprising use of an antibiotic in the manufacture of a medicament for the treatment of a bacterial infection.
34. The use of anyone of claims 14 to 33, wherein said subject is a human.
35. A method of treating a bacterial infection, comprising: administering a bioactive self-assembling peptide according to any one of claims 1 to 8 to a subject in the need thereof.

36. A method of treating a bacterial infection, comprising: administering a nanofiber of claim 9 to a subject in the need thereof.
37. A method of treating a bacterial infection, comprising: administering a hydrogel of any one of claims 10 to 13, to a subject in the need thereof.
38. The method of any one of claims 35 to 37, further comprising administering an antibiotic.
39. The method of any one of claims 35 to 38, wherein said subject is a human.
40. A method of treating a wound in a subject, comprising: administering a bioactive self-assembling peptide according to any one of claims 1 to 8 to a subject in the need thereof.
41. A method of treating a wound in a subject, comprising: administering a nanofiber of claim 9 to a subject in the need thereof.
42. A method of treating a wound in a subject, comprising: administering a hydrogel of any one of claims 10 to 13, to a subject in the need thereof.
43. The method of any one of claims 40 to 42, further comprising administering an antibiotic.
44. The method of any one of claims 40 to 43, wherein said subject is a human.
45. A kit comprising: a bioactive self-assembling peptide according to any one of claims 1 to 8, a container, and optionally instructions for the use thereof.
46. A kit comprising: a nanofiber of claim 9, a container, and optionally instructions for the use thereof.
47. A kit comprising: a hydrogel according to any one of claims 10 to 13, a container, and optionally instructions for the use thereof.
48. The kit of any one of claims 45 to 47, further comprising an antibiotic.

(RADA)₄: AC-RADARADARADARADA-CONH₂:




(SEQ ID NO: 1)

FIG. 1A

(RADA)₄-GG-(PAMP-12): AC-RADARADARADARADA-GG-FRKKWINKWALSR-CONH₂

(SEQ ID NO: 2)

FIG. 1B



(SEQ ID NO: 2)

FIG. 1C

2/9




FIG. 2

3/9




FIG. 3

4/9




FIG. 4

5/9




FIG. 5




FIG. 6A




FIG. 6B

7/9




FIG. 7

8/9




FIG. 8




FIG. 9A





FIG. 9B

(RADA)₄: AC-RADARADARADARADA-CONH₂:




(SEQ ID NO: 1)

FIG. 1A

(RADA)₄-GG-(PAMP-12): AC-RADARADARADARADA-GG-FRKKWNKWALSR-CONH₂

(SEQ ID NO: 2)

FIG. 1B



(SEQ ID NO: 2)

FIG. 1C